Company intelligence / Profile preview

Intero Biosystems

Ann Arbor, Michigan, United Statesinterobiosystems.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Intero Biosystems has developed GastroScreen, the first stem cell-derived human “mini-gut” organoid that replicates key cell types, spatial architecture, and functions of the human intestine. This platform enables comprehensive preclinical safety and efficacy testing of drugs on a physiologically relevant model before entering clinical trials. The company has demonstrated proof-of-concept for both healthy tissue modeling for toxicity studies and diseased tissue modeling for efficacy screening, such as in intestinal fibrosis.

Therapeutic areas: OtherGastroenterology
Modalities: Organoids
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Intero Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intero Biosystems.

Explore the full profile